13F Holdings
中文EN

UTMD UTAH MEDICAL PRODUCTS INC

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 706698 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-9.6%
TTM net income YoY-8.4%
TTM EPS YoY-5.6%
Revenue 3-yr CAGR-12.1%
Net income 3-yr CAGR-14.3%

Margins

Gross margin57.7%
Operating margin29.9%
Net margin30.5%
FCF margin31.1%
EBITDA margin32.4%

Returns

ROE8.8%
ROA8.5%
ROIC (approx.)23.7%
Asset turnover0.28x

Leverage & solvency

Liabilities / assets4.1%
Debt / equity0.00x
Current ratio21.23x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.08x
Accruals ratio-0.7%
Payout ratio37.0%
Capex / revenue1.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$38.52M$40.90M$50.22M$52.28M$49.05M
Cost of revenue$16.52M$16.76M$20.19M$20.09M$18.14M
Gross profit$22.00M$24.14M$30.04M$32.20M$30.92M
R&D expense$668,000$813,000$560,000$493,000$526,000
SG&A expense$7.88M$7.83M$11.02M$10.41M$10.10M
Operating income$11.40M$13.59M$16.78M$19.79M$18.88M
Pretax income$14.11M$16.80M$20.09M$20.66M$19.06M
Income tax$2.82M$2.93M$3.45M$4.19M$4.27M
Net income$11.29M$13.87M$16.64M$16.47M$14.79M
EBITDA$12.23M$14.32M$17.40M$20.40M$19.52M
EPS (basic)3.483.964.584.534.05
EPS (diluted)3.483.964.574.524.04
Weighted avg. shares (diluted)3.24M3.50M3.64M3.64M3.66M
Balance sheet
Cash & equivalents$85.76M$82.98M$92.87M$75.05M$60.97M
Receivables$3.52M$4.09M$3.39M$5.54M$5.13M
Inventory$7.93M$8.81M$9.58M$8.81M$6.60M
Current assets$97.74M$96.33M$106.27M$89.92M$73.16M
PP&E, net$9.91M$9.76M$10.55M$10.22M$10.62M
Goodwill$14.05M$13.58M$13.69M$13.35M$14.10M
Intangibles$840,000$2.87M$4.95M$10.38M$17.76M
Total assets$122.54M$122.54M$135.46M$123.87M$115.64M
Current liabilities$2.60M$3.76M$4.71M$5.96M$3.75M
Long-term debt$225,000$282,000$295,000$0$0
Total debt$225,000$282,000$295,000$0$0
Total liabilities$3.27M$5.11M$7.14M$9.62M$8.50M
Shareholders' equity$119.27M$117.43M$128.31M$114.25M$107.14M
Net debt-$85.53M-$82.69M-$92.57M-$75.05M-$60.97M
Shares outstanding3.19M3.33M3.63M3.63M3.65M
Cash flow statement
Operating cash flow$14.69M$14.83M$22.28M$21.15M$21.20M
Capital expenditure$371,000$230,000$639,000$809,000$552,000
Free cash flow$14.32M$14.60M$21.64M$20.34M$20.65M
Investing cash flow-$371,000-$208,000-$639,000-$818,000-$552,000
Financing cash flow-$12.34M-$23.84M-$4.17M-$5.48M-$10.90M
Depreciation & amortization$826,000$730,000$623,000$612,000$636,000
Stock-based compensation$373,000$256,000$225,000$183,000$166,000
Dividends paid$3.98M$4.26M$4.28M$3.16M$11.46M
Share buybacks$8.36M$19.97M$0$2.50M$0

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.